Harausz E, Cox H, Rich M, Mitnick C D, Zimetbaum P, Furin J
Tuberculosis Research Unit, Case Western Reserve University, Cleveland, Ohio, USA.
Division of Medical Microbiology and the Institute for Infectious Disease and Molecular Medicine, University of Cape Town, South Africa.
Int J Tuberc Lung Dis. 2015 Apr;19(4):385-91. doi: 10.5588/ijtld.14.0335.
Electrocardiographic (ECG) monitoring is recommended for some of the new and re-purposed drugs used in the treatment of multidrug-resistant tuberculosis (MDR-TB), as these drugs have been shown to prolong the QTc interval. ECG monitoring is relatively new in the management of TB patients, and has several implications for programs and providers. This review discusses what is known about QTc prolongation and the medications currently being studied or used to treat MDR-TB, and discusses strategies for managing QTc prolongation in the context of treating such a serious infectious disease. It also reviews some major implications of ECG monitoring in the field, including interpretation of ECGs and QTc intervals, management of patients with prolonged QTc intervals, and contextualizing the risk of QTc prolongation for patients being treated for MDR-TB.
对于治疗耐多药结核病（MDR-TB）使用的一些新药和重新利用的药物，建议进行心电图（ECG）监测，因为这些药物已被证明会延长QTc间期。ECG监测在结核病患者管理中相对较新，对项目和提供者有若干影响。本综述讨论了关于QTc延长以及目前正在研究或用于治疗MDR-TB的药物的已知情况，并讨论了在治疗这种严重传染病的背景下管理QTc延长的策略。它还回顾了该领域ECG监测的一些主要影响，包括心电图和QTc间期的解读、QTc间期延长患者的管理，以及将接受MDR-TB治疗患者的QTc延长风险置于具体情境中。
